Navigation Links
Antibodies for new rotavirus vaccines
Date:7/17/2012

CSIRO has been contracted by PATH (Program for Appropriate Technology in Health) to produce antibodies on a large scale that will aid the development of new, safe, affordable and effective vaccines against rotavirus, a major cause of severe and fatal diarrhoea in young children worldwide.

Rotavirus kills nearly half a million children every year, 85 per cent of whom live in developing countries. The virus is one of the most common causes of hospital and emergency admissions for children under five in Australia.

Since the introduction of two rotavirus vaccines, Rotarix and RotaTeq, to Australia's National Immunisation Program in 2007, hospitalisations of children under five years of age due to rotavirus gastroenteritis have been reduced by over 70 per cent.

PATH, an international not-for-profit organisation, is working to increase access to and effectiveness of existing commercial rotavirus vaccines worldwide, while also working with emerging-country vaccine manufacturers to speed up the development of safe, effective, and more affordable new rotavirus vaccines.

"CSIRO will produce a large quantity of antibodies specific to the strains of rotavirus that are in the vaccines our partners are developing, which will serve as important material for our project," said Dr Georges Thiry, director of PATH's rotavirus vaccine development project.

"New vaccines and suppliers will increase the availability of rotavirus vaccines and increase competition, which in turn will help make all of the rotavirus vaccines on the market more affordable and accessible to the world's most vulnerable children."

Dr George Lovrecz, group leader for CSIRO's protein production and fermentation group, is confident that CSIRO's expertise from the tissue culture and purification teams will deliver excellent results.

"We are proud to be assisting this groundbreaking project that is working to help save the lives of children in the world's poorest countries," he said.

CSIRO will use their recombinant protein production facility in Clayton, Victoria, for the large-scale production of the antibodies.

"This unique, state-of-the-art facility will allow us to produce enough antibodies to supply PATH's partners for the next five years," said Dr Lovrecz.

"We will be producing six antibodies that will be used to test the quality of the rotavirus vaccines being developed."

The antibodies, originally prepared by Dr Carl Kirkwood from the Murdoch Childrens Research Institute, will be used by PATH's manufacturing partners in China, Brazil, and India and by the United States' National Institutes of Health.


'/>"/>

Contact: Merrin Fabre
Merrin.Fabre@csiro.au
61-395-458-362
CSIRO Australia
Source:Eurekalert

Related medicine news :

1. Antibodies from rabbits reduce risks associated with unrelated donor stem cell transplantation
2. Antibodies from rabbits reduce risks associated with
3. Antibodies reverse type 1 diabetes in new immunotherapy study
4. ACP Immunization Advisor app makes it easier for doctors to identify vaccines for patients
5. Control gene for conveyor belt cells could help improve oral vaccines, treat intestinal disease
6. OHSU Oregon National Primate Research Center develops new, safer method for making vaccines
7. World Health Assembly endorses new plan to increase global access to vaccines
8. Study: More Pre-Teens Get Vaccines When Middle Schools Require Them
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: